CLP1 is a RNA kinase involved in tRNA splicing. Recently, CLP1 kinase-dead mice were shown to display a neuromuscular disorder with loss of motor neurons and muscle paralysis. Human genome analyses now identified a CLP1 homozygous missense mutation (p.R140H) in five unrelated families, leading to a loss of CLP1 interaction with the tRNA splicing endonuclease (TSEN) complex, largely reduced pretRNA cleavage activity, and accumulation of linear tRNA introns. The affected individuals develop severe motor-sensory defects, cortical dysgenesis, and microcephaly. Mice carrying kinase-dead CLP1 also displayed microcephaly and reduced cortical brain volume due to the enhanced cell death of neuronal progenitors that is associated with reduced numbers of cortical neurons. Our data elucidate a neurological syndrome defined by CLP1 mutations that impair tRNA splicing. Reduction of a founder mutation to homozygosity illustrates the importance of rare variations in disease and supports the clan genomics hypothesis.
INTRODUCTION
In order to translate genomic information, tRNAs undergo essential posttranscriptional modifications, including chemical alterations, excision of introns followed by exon ligation, removal of 5 0 leader and 3 0 trailer sequences, and CCA addition (Phizicky and Hopper, 2010) . Although tRNA synthesis and processing are essential to all cells, mutations in genes involved in tRNA transcription and maturation appear to preferentially affect the function of neurons. There is an emerging class of neurological disorders resulting from abnormal tRNA biogenesis. Mutations in genes encoding various aminoacyl tRNA synthetases result in Charcot-Marie-Tooth neuropathy (GARS, KARS, YARS, AARS, and HARS) (Antonellis et al., 2003; Jordanova et al., 2006; Lee et al., 2006; McLaughlin et al., 2010; Vester et al., 2013) , spastic ataxia with leukoencephalopathy (MARS2) (Bayat et al., 2012) , distal spinal muscular atrophy (GARS) (Antonellis et al., 2003) , or pontocerebellar hypoplasia type 6 (PCH6) (RARS2) (Edvardson et al., 2007) . Another distinct group of disorders due to abnormal tRNA maturation is pontocerebellar hypoplasias associated with defects in genes encoding subunits of the tRNA-splicing TSEN complex, including mutations in TSEN2, TSEN34, and TSEN54 (Budde et al., 2008; Cassandrini et al., 2010) .
CLP1 was the first mammalian RNA kinase to be discovered (Weitzer and Martinez, 2007) . We have recently shown that CLP1 acts in concert with the TSEN complex to remove introns present within the anticodon loop of numerous pre-tRNAs (Hanada et al., 2013) . Clp1 kinase-dead (Clp1 K/K ) mice exhibit a progressive loss of spinal motor neurons associated with axonal degeneration in peripheral nerves, denervation of neuromuscular junctions, ultimately resulting in impaired motor functions, muscle weakness, paralysis, and fatal respiratory failure (Hanada et al., 2013) . Human CLP1 mutations have not been reported, and it is not known whether such mutations would also affect the human nervous system. Here, we report the identification of a human CLP1 mutation that impairs tRNA splicing in vitro and causes a neurological syndrome involving both the central nervous system (CNS) and peripheral nervous system (PNS). All five families share a haplotype of common variants surrounding CLP1, supporting the notion that clan genomics contributed to the molecular pathology of disease in this lineage (Lupski et al., 2011) .
RESULTS

A Neurological Syndrome Defined by CLP1 Mutations in Humans
We studied patients with evidence of brain malformations and microcephaly who shared similar facial characteristics and global growth and also developmental delays, severe intellectual disabilities, and seizures refractory to treatment (Figures 1 and S1A available online). MRI revealed brain abnormalities of differing severities, including cortical dysgenesis marked by a simplified gyral pattern, particularly in the anterotemporal regions, mild or focal cerebellar vermian volume loss (BAB3520 and BAB4771), and thinning of the brain stem (BAB3520) (Figure 1) . None of the 11 subjects studied could either ambulate or sit without support. They all have poor (10 to 15 s) head control, whereas the youngest patient (BAB5318; 6 months old)
has not yet achieved head support. All patients had hypertonia and increased deep tendon reflexes. Electrophysiological studies revealed objective evidence for marked axonal sensorimotor neuropathies ( Figure 2 and Table S1 ). In addition to these characteristic neurologic findings, careful clinical evaluation revealed that the patients exhibit facial features that appear distinctive, including high arched eyebrows, prominent eyes, long palpebral fissures and eyelashes, broad nasal roots, and hypoplasic alae nasi ( Figure 1 ). Individual patient clinical details are provided in the Extended Experimental Procedures.
Targeted exome capture and whole-exome sequence (WES) of four affected individuals (BAB3401, 3402, 3421, and 3422), two from each nuclear family (HOU1338 and HOU1333, respectively) (Figures 1 and S1B) , identified a homozygous c.G419A (p.R140H) (chr11:g.57,427,367 G > A [hg19], NM_006831.2) nonsynonymous substitution in the CLP1 gene located on chromosome 11q12.1 ( Figure 3A) , in which mutations have not been associated previously with human disease. The R140H mutation has not been reported in the 1000 Genomes Project (http://www.1000genomes.org) or other large-scale exome sequencing projects, including the exome variant server, NHLBI GO Exome Sequencing Project (ESP) in Seattle, Washington (http://evs.gs.washington.edu/EVS/), and the ''in-house''-generated exomes from more than 2,500 individuals at the Baylor College of Medicine (BCM) Human Genome Sequencing Center and BCM Whole Genome Laboratory Database (MGL; http://www.bcm.edu/geneticlabs/; with more than 1,000 individuals tested for diagnostic purposes) and the Atherosclerosis Risk in Communities Study (ARIC) Database (http://drupal.cscc. unc.edu/aric/).
Because all four subjects from the original two kindreds undergoing exome sequencing presented with the same clinical syndrome, we hypothesized that CLP1 mutations could cause a clinically distinguishable phenotype. We therefore reanalyzed our brain malformation cohort focusing on patients with similar CNS and PNS abnormalities and dysmorphic features and found three additional families with consanguinity; these subjects were unrelated to the former two families and had no known relation to each other. Using this phenotypedirected approach, Sanger sequencing of CLP1 in the latter three families revealed the same R140H mutation in the homozygous state in all seven additional affected individuals, heterozygous carrier states in the parents and one unaffected male sibling, and homozygous wild-type status in one unaffected female sibling (HOU1380, HOU1926, and HOU1981) (Figures 1 and S1B) , which is consistent with Mendelian recessive expectations.
None of the families in our study were previously aware of a relationship. All five families belong to the same ethnic group and reside in the same geographic area of Eastern Turkey. We therefore hypothesized that each family inherited the same mutation from a common ancestor in which this founder mutation occurred. To investigate this, we performed genome-wide SNP microarray analysis on 19 individuals. Pairwise identity-bydescent (IBD) estimation in PLINK (Purcell et al., 2007) matched reported familial relationships exactly but did not suggest recent common ancestry among these seemingly unrelated individuals (pi-hat 0-0.04). Notably, all families share an 11.5 Mb haplotype in the CLP1 region, which spans the centromere and is homozygous in the affected children ( Figure 3A ). For the last family (HOU1981; samples BAB4980 and BAB4981), the regions with absence of heterozygosity were experimentally determined from WES data that revealed homozygosity of the CLP1 region in these two affected individuals ( Figure 3A) . Thus, we have identified a defined clinical syndrome with progressive central and peripheral nervous system defects in 11 affected children from five families, all of whom carry a homozygous CLP1 R140H mutation.
Molecular Modeling
Analysis of the human protein-protein interaction network revealed interactions between CLP1 and members of both mRNA 3 0 end processing and the tRNA-splicing TSEN complex ( Figure 3B ). In silico analyses suggest CLP1 is also connected to a number of human-disease-associated genes involved in DNA repair and cell-cycle control such as p53 and VRK1, as well as tRNA metabolism ( Figure 3B ). Analysis on the molecular evolution of the CLP1 mutation showed that the R140H amino acid change affects an arginine residue that is highly conserved from human to zebrafish ( Figure 3C ).
The CLP1 R140H mutation is predicted to be ''damaging or disease causing'' by different bioinformatics algorithms (PolyPhen-2, SNAP, SIFT, and Mutation Taster). Inspection of the yeast Clp1 crystal structure provides a possible explanation for this effect. In the yeast protein, the corresponding lysine residue (position 149) protrudes from the middle domain toward the N-terminal domain, determining the relative orientation of the two domains to each other ( Figure 3D ). Whereas an arginine, as seen in higher eukaryotes, may exert a similar organizing effect, a histidine side chain is too short to mediate this interaction.
We thus speculate that the R140H mutation results in an altered domain arrangement that is incompatible with binding potential partner proteins. We further predict that the R140H mutation should not abolish the RNA kinase activity of the enzyme, which is associated with the middle domain containing the catalytic site.
Perturbed CLP1-TSEN Complex Integrity Impairs PretRNA Cleavage Based on structure-prediction analysis, we investigated whether the R140H mutation affects CLP1 function. We first assayed RNA kinase activity of recombinant glutathione S-transferase (GST)-tagged wild-type CLP1, kinase-dead CLP1 (K127A mutation), and CLP1 with the R140H mutation expressed in E. coli ( Figures 4A and 4B ) and FLAG-CLP1 complexes containing these CLP1 versions ectopically expressed and affinity purified from HEK293 cells ( Figure 4C ). Whereas kinase activity was abolished in the K127A mutants, as previously reported (Weitzer and Martinez, 2007) , the R140H mutant protein retained kinase activity, albeit at a reduced level when compared to the wild-type CLP1 protein ( Figures 4B and 4C ). We next tested for Table S1. interactions between mutant CLP1 and members of the TSEN complex. Intriguingly, the interaction of R140H CLP1 with TSEN2, TSEN54, or TSEN34 was markedly reduced ( Figure 4D ).
In line with loss of CLP1-TSEN complex integrity, pre-tRNA cleavage activity of purified R140H CLP1 was almost abolished ( Figure 4E ). Of note, the kinase-dead CLP1 K127A mutation also (Noble et al., 2007) illustrating its domain architecture. The highlighted Lys149 is positioned at the interface of theshowed impaired interaction with TSEN proteins ( Figure 4D ), correlating with decreased pre-tRNA cleavage activity (Figure 4E ) (Hanada et al., 2013) . We next isolated and established fibroblast cultures using skin biopsies from patients (BAB3401 and BAB3402) and their parents (BAB3845 and BAB3846) and prepared extracts equalizing for protein concentrations. In nuclear extracts from patient fibroblasts, there was only a minor detectable pre-tRNA cleavage activity ( Figure 4F ), and RNA kinase activity was reduced ( Figure 4G ). Because the CLP1-TSEN complex can be purified from cytoplasmic extracts of HeLa cells (Weitzer and Martinez, 2007) , we also tested RNA kinase activity in the cytoplasm of patient fibroblasts. Here, the activity was reduced in comparison to parental cells (Figures 4H). Another tRNA splicing-related biochemical activity-RNA ligation activity as assessed by an interstrand ligation assay in nuclear extracts (Popow et al., 2011) -did not correlate with the occurrence of the CLP1 R140H mutation in fibroblasts ( Figure S2A ). Western blot analysis confirmed the presence of CLP1, TSEN proteins, and the tRNA ligase HSPC117 in nuclear extracts of patient cells (Figure S2B) . Although levels of CLP1 appeared reduced in nuclear extracts, CLP1 was present at similar levels in the cytoplasm of parental and patient cells ( Figure S2C ). Thus, our in vitro assays for analyzing purified protein complexes showed that the mutation does not abrogate kinase function but severely affects the association of CLP1 with components of the (C) RNA kinase assay using protein complexes containing FLAG-CLP1 wild-type, FLAG-CLP1 K127A, and FLAG-CLP1 R140H affinity purified from stably expressing HEK293 cells. HEK293 cells without expression of any tagged proteins served as a control. Assays were carried out with undiluted and 1:3-diluted eluates as indicated.
(D) Western blotting for TSEN components interacting with affinity-purified FLAG-CLP1 wild-type, FLAG-CLP1 K127A, and FLAG-CLP1 R140H.
(E) Pre-tRNA cleavage assay of affinity-purified FLAG-CLP1 wild-type, FLAG-CLP1 K127A, and FLAG-CLP1 R140H complexes incubated with an internally labeled intron-containing yeast pretRNA TSEN complex, resulting in impaired pre-tRNA cleavage. This is consistent with impaired tRNA splicing observed in nuclear extracts from patient fibroblasts.
CLP1 R140H Mutant Fibroblasts Accumulate Introns
Derived from Different tRNA Genes We next isolated total RNA from parental and patient fibroblasts and performed Northern blot analysis using probes detecting tRNAs genomically encoded as intron-less versions (i.e., Met-CAT) or intron-containing versions (Ile-TAT, Tyr-GTA, Leu-CAA, and Arg-TCT). There was no significant difference in mature tRNA steady-state levels as exemplified by using probes against the exon junction and the 5 0 exon detecting multiple tRNAs of the same isotype, so-called pan-probes, in parental and patient fibroblasts (Figures 5A and 5C, top; Figures S2D and S2F) . In addition, we performed RNA deep sequencing and subjected reads to a quantitative bioinformatics pipeline that failed to reveal consistent differences in global mature tRNA levels between both parental and patient cell lines (Table S2) . We also performed Northern blot analysis to assess pre-tRNA levels using 5 0 exon pan-probes and intron probes detecting specific tRNA genes. We were not able to detect consistent global differences either in steady-state levels of pre-tRNAs between both parental and patient fibroblast cell lines or by comparing results obtained from either approaches ( Figures 5A-5C [middle], S2D-S2E, and S2G and data not shown). Interestingly, both by Northern blotting and deep sequencing analysis, we reproducibly detected an accumulation of tRNA introns derived from three particular tRNA genes (Ile-TAT Chr19.trna10, Ile-TAT Chr2.tRNA5, and Tyr-GTA Chr2.tRNA2; Figures 5A and 5C [middle] , 5B, and S3A-S3C and Table S3 ) in patient fibroblasts. Biochemical analysis using RNase R treatment that digests linear, but not circular, RNA revealed that Ile-TAT (Chr19.trna10) introns are linear ( Figure S3D ). Because these introns can be ligated to a 3 0 hydroxy-terminating RNA linker only upon prior 5 0 phosphorylation, we conclude that introns display a 5 0 hydroxy group ( Figure S3E ). Thus, our Northern analysis and deep sequencing data indicate that the CLP1 R140H mutation in fibroblasts influences processing of pre-tRNAs, resulting in the accumulation of linear tRNA introns, whereas pre-and mature tRNA levels remain largely unaffected.
Microcephaly in Clp1 Defective Mice
We recently reported progressive loss of motor neurons, axonal motor neuropathy, and muscle paralysis leading to death in kinase-defective CLP1 K127A (Clp1 K/K ) mutant mice (Hanada et al., 2013) , a phenotype consistent with the observed impairment of motor functions in our patients, including features of sensorimotor axonal neuropathy. Of note, on a B6 background, all Clp1 K/K newborn mice die due to impaired innervations of the diaphragm, whereas, on a CBA/J background, Clp1 K/K mutant mice grow to adulthood and progressively lose spinal motor neurons and motor functions (Hanada et al., 2013) . Given the significant microcephaly noted in patients carrying the CLP1 R140H mutation (Figures 1 and S1A ), we wondered whether we had missed a brain phenotype in our mutant Clp1 K/K mice, also considering fundamental differences between human and rodent brain development (Lancaster et al., 2013 (Figure S4C ), which describes the elongation of the brain during normal development. Moreover, using geometric structural analysis, we observed markedly reduced cortical thickness throughout the entire cortex ( Figures  6B and S4D ). This difference is particularly prominent in the frontal and somatosensory-motor areas of the cortex (see red and yellow areas in Figures 6B and S4D ). The reduction of cortical thickness was confirmed histologically (Figures S4E and S4F ).
Immunohistochemical analysis with antibodies against neuronal nuclear antigen (NeuN) to detect neurons showed normal cortical layering ( Figure S5A ). Importantly, in line with reduced brain size and reduced cortical thickness, we found reduced numbers of NeuN + neurons in the neocortex of adult Clp1 K/K mice as compared to their wild-type littermate controls ( Figure 6C ). By contrast, microglial cells, as detected by immunostaining for ionized calcium binding adaptor molecule 1 (Iba-1), appeared to be increased in the neocortex of Clp1 K/K mice, albeit not to significant levels ( Figures S5B and S5C) . Numbers of glial fibrillary acidic protein (GFAP)-positive astrocytes were apparently not affected in the hippocampus ( Figures  S5D and S5E Figure 6B and data not shown). Thus, similar to humans with CLP1 R140H mutations, these data show that mice carrying kinase-dead Clp1 mutation exhibit microcephaly, in particular due to reduced numbers of cortical neurons. When we analyzed Clp1 K/K embryos on the lethal B6 mouse background, we did not observe significant total brain weight differences between wild-type and Clp1 K/K mice at embryonic day 16.5 (E16.5); however, Clp1 K/K mice showed significantly decreased brain weights at E18.5 and reduced brain sizes as determined by histology ( Figures 7A and S6A-S6C Figure S3C to compare the accumulation of intron reads relative to parental (BAB3846) fibroblasts.
( Figure S6D ). Moreover, in 3D whole-brain reconstructions using 15 Tesla MRI imaging, we also observed markedly reduced brain volumes at E18.5 but comparable brain volumes at E16.5 (Figures 7B and 7C ). At E18.5, the main reduction in brain volume was observed in the cortex of Clp1 K/K mice, with additional significant reductions in the volume of the bulbus olfactorius, whereas the volumes of the cerebella were comparable between control and Clp1 K/K littermates ( Figures 7B and S6E ). Cortical thickness was comparable between E16.5 Clp1 +/+ and Clp1
embryos, but it was markedly reduced in E18.5 Clp1 K/K embryos as compared to their wild-type littermate controls ( Figure 7B ). Shape analysis of the brain geometry by principal component analysis (PCA) further revealed that, in the control, all three spatial axes increased significantly from E16.5 to E18.5, but in the Clp1 K/K embryos, the third PCA (dorso-ventral direction)
had even decreased, whereas the first PCA (anterior-posterior direction) and the second PCA (caudal-rostral direction) were apparently normal in the Clp1 K/K mice ( Figure S6F ), indicating impaired dorso-ventral expansion of the cortex. The latter is also reflected by the fact that only wild-type control brains exhibit a significant decrease in cortical roundness due to changes in brain geometry ( Figure S6G ). These data show that mice carrying a homozygous CLP1 K127A kinase-dead mutation exhibit impaired expansion of the brain cortex, resulting in microcephaly.
Similar to adult Clp1 K/K mice, mutant E18.5 embryos had reduced numbers of Tbr1 + neurons as compared to control littermates; at E16.5, the numbers of Tbr1 + neurons were comparable among control and Clp1 K/K embryos ( Figures 7D, 7E , and S6H).
Numbers and distributions of Iba-1 + microglial cells were , embryos ( Figure S7G ). Importantly, we detected a higher number of apoptotic cells throughout the brain of E16.5 and, in particular, E18.5 Clp1 K/K embryos (Figure 7F ). To test whether neuronal progenitors are more susceptible to death in Clp1 mutant embryos, we prepared neural precursor cells (NPCs) from E14.5 control and Clp1 K/K embryos.
Importantly, Clp1 K/K neural precursor cells exhibited enhanced cell death in basal growth conditions (using EGF and FGF), under oxidative stress, as well as following growth factor withdrawal; this enhanced cell death could be blocked using the pancaspase inhibitor zVAD, as well as the antioxidant N-acetyl-L-cysteine (NAC) ( Figure 7G ). These data indicate that Clp1 K/K embryos have normal numbers and proliferation of neuronal progenitors, but neuronal progenitor cells undergo enhanced cell death, resulting in reduced numbers of cortical neurons.
DISCUSSION
In this study, we provide genomic, genetic, and molecular modeling and biochemical and animal model evidence for the involvement of CLP1 in a complex neurological phenotype that includes both the CNS and PNS. We identified the same homozygous rare variant, R140H, of the CLP1 gene in 11 individuals affected with this neurological syndrome from five families using WES and candidate gene sequencing. Further genetic analysis revealed that these families share the same haplotype block encompassing the CLP1 region. These data support the concept of clan genomics (Lupski et al., 2011) in that a rare variant in the population is concentrated in a lineage that introduced the variant, either by de novo mutation or by immigration and subsequent founder effect. In the patients identified here, the rare R140H mutation was reduced to homozygosity. Our genomic and genetic data indicate that a rare variant allele arose in a distant common ancestor, segregated through the generations, and was reduced to homozygosity by apparent consanguinity. Genomic approaches to rare variant detection in Mendelizing disease traits may eventually provide new insights into both the genetic and molecular basis of disease, as well as reveal unexpected consequences of dysfunction of basic biological processes such as RNA metabolism.
Our findings reveal cortical dysgenesis with predominant forebrain involvement by MRI and no overt evidence for midbrain or prominent cerebellar abnormalities. Our mouse studies support predominant cortical cellular apoptosis likely responsible for the uniform microcephaly observed during development in mice and postnatally in all human subjects with homozygous R140H alleles. A parallel study in this issue of Cell (Schaffer et al., 2014) reported CLP1 mutation in association with a clinical phenotype of pontocerebellar hypoplasia; they also report a R140H founder mutation. In a zebrafish model organism study of Clp1 mutation, they show TUNEL staining, revealing dramatic increase specific to forebrain and hindbrain. Forebrain staining supports both our mouse and human findings in which predominant cortical involvement is observed.
Our data provide insights into the biology of disease, including cortical dysgenesis. Mutations in proteins involved in RNA modifications have been associated previously with preferentially or exclusively either CNS or PNS pathology. For instance, mutations in EXOSC3, TSEN54, TSEN2, and TSEN34 are known to cause neurological phenotypes that manifest in the brain stem and cerebellum, causing Pontocerebellar hypoplasia (PCH) PCH1B, PCH2A, PCH4, PCH2B, and PCH2C, but little is known regarding potential PNS involvement, as the results of nerve conduction studies have not been reported (Budde et al., 2008; Renbaum et al., 2009; Wan et al., 2012) . Conversely, mutations in tRNA synthetase genes, such as GARS, KARS, YARS, AARS, and HARS, are predominantly associated with Charcot Marie Tooth neuropathy, distal spinal muscular atrophy, and other PNS disorders without significant CNS involvement (Antonellis et al., 2003; Jordanova et al., 2006; Lee et al., 2006; McLaughlin et al., 2010; Vester et al., 2013) .
Our biochemical experiments provide evidence that the CLP1 R140H mutation impairs tRNA exon generation, most likely due to decreased interaction between mutant CLP1 and the TSEN complex. Together with our previous study showing that a kinase-dead Clp1 K127A mutation results in reduced pre-tRNA cleavage by affecting CLP1-TSEN complex integrity (Hanada et al., 2013) , we propose that an intact CLP1-TSEN association is essential for efficient tRNA splicing. The fact that the CLP1 R140H mutant shows RNA kinase activity but is unable to associate with TSEN components will support the need for future studies on modeling potential CLP1-TSEN interaction platforms that are, in contrast to the kinase-dead CLP1 K127A mutation, uncoupled from its ATP binding and/ or hydrolysis activity.
We further show that the global steady-state levels of mature tRNAs in fibroblasts are not influenced by the CLP1 R140H mutation, suggesting the existence of backup mechanisms that ensure sufficient levels of mature tRNAs despite the undetectable pre-tRNA cleavage activity observed in nuclear extracts from patient cells. No obvious increase in general pre-tRNA levels was observed in patient fibroblasts, and therefore, it is unlikely that enhanced Pol III transcription of intron-containing tRNA genes could compensate for inefficient pre-tRNA cleavage. Analogous to the accumulation of 5 0 leader-exon tRNA fragments in cells and tissues of Clp1 K/K mice (Hanada et al., 2013) , we detected increased levels of isoleucine and tyrosine tRNA introns in R140H patient fibroblasts. These introns are linear and harbor 5 0 OH groups, properties that are expected for a reaction product after pre-tRNA cleavage and prior to a potential 5 0 phosphorylation by CLP1 (Weitzer and Martinez, 2007) or circularization by the tRNA ligase (Popow et al., 2011) . Future work will have to address whether accumulation of linear introns is a consequence of a defective release from a TSEN complex in CLP1 R140H patient cells, thus being not exposed to cellular nuclease activities. Further studies may also provide insights into whether generation of tRNA processing intermediates is a consequence of mutations in the CLP1 gene and potential functions of these tRNA splicing byproducts. On top of an MRI slice iso-surface, 3D renderings are shown for the bulbus olfactorius (dark blue), cerebellum (light blue), and the cortex. The cortex is rainbow
(legend continued on next page)
We demonstrated that mutations in CLP1 impair functioning of neurons and lead to abnormalities of both the CNS and PNS. Our patients present with peripheral nerve dysfunction as evidenced by abnormal electrophysiological studies showing axonal neuropathy affecting both motor and sensory nerves. These observations were universal in the eight affected individuals with CLP1 mutations for whom NCVs were assessed. Moreover, all patients exhibit global cortical dysgenesis and microcephaly, which is suggestive of global CNS dysfunction. Based on these human phenotypes, we speculated that our mutant mice carrying a kinase-inactivating CLP1 mutation might also exhibit abnormalities of both the CNS and PNS. Indeed, using histological analyses and 3D reconstruction from MRI images, mice carrying a homozygous CLP1 K127A kinase-dead mutation exhibit marked microcephaly, in particular due to reduced numbers of cortical neurons. Mechanistically, this phenotype appears to be progressive and can be attributed to enhanced apoptosis of neuronal progenitor cells at basal conditions and in response to oxidative stress and growth factor withdrawal. Whether additional mechanisms contribute to the observed microcephaly in mice and whether these uncovered mechanisms also extend to humans will need to be evaluated in future experiments. It is striking that the clinical presentation of patients with CLP1 mutations is nearly identical to one we observed in patients with VRK1 mutations (Gonzaga-Jauregui et al., 2013), especially in the neurological presentation (progressive weakness), brain imaging studies (cortical dysgenesis, microcephaly), and nerve conduction velocity (NCV) (axonal neuropathy). From our network analysis, CLP1 and VRK1 are molecular interactors, and it has been reported that VRK1 can phosphorylate p53 (Valbuena et al., 2006 (Valbuena et al., , 2011 . We recently reported that kinase-dead CLP1 sensitizes motor neurons and fibroblasts to death following oxidative stress via a p53-mediated cell death pathway; genetic inactivation of p53 completely rescued the neonatal lethal phenotype of Clp1 K/K mice on a B6 background (Hanada et al., 2013) . Thus, based on our published genetic data in mice (Clp K/K ) now complemented by genomic approaches in human rare disease studies (CLP1 and VRK1), it appears that the neurotoxic CLP1-p53 pathway we have identified in mouse is also conserved and operates in humans and is critical to neuron function.
EXPERIMENTAL PROCEDURES Patients
This study was approved by the Institutional Review Board at Baylor College of Medicine, and informed consent was obtained from all subjects prior to enrollment in the project. All subjects were evaluated by one or more pediatric neurologists and clinical geneticists experienced with brain malformation phenotypes. Genomic DNA was extracted from blood based on the manufacturer's protocol (QIAGEN Sciences).
Whole-Exome Sequencing
Four initial affected individuals (BAB3401, BAB3402, BAB3421, and BAB3422) underwent targeted whole-exome capture using the BCM HGSC Core design followed by Illumina HiSeq massively parallel sequencing through the BaylorHopkins Center for Mendelian Genomics (BHCMG) initiative. An average of 10 Gb of raw sequence data were produced and subsequently mapped and aligned to the reference human genome sequence GRCh37/Hg19 using the BWA algorithm with an average depth of coverage of 1203 (median coverage = 913); $92% of the bases were covered at 203. Variants were called and annotated using an in-house-developed bioinformatics pipeline. Analysis of variants was initially performed in search for shared variants between the pairs of affected siblings under a recessive model of inheritance and later filtered for high-frequency and commonly observed variants.
Sanger PCR Confirmation and Segregation Studies
To confirm the mutation detected by exome sequencing and to perform segregation analysis, standard PCR was carried out as previously described (Pehlivan et al., 2012 ) by using CLPF1: 5 0 -AGAGCTGACCCGAAACAAGA-3 0 and CLPR1: 5 0 -CCAGCTGAGAAAATGCAGTG-3 0 primers. Amplification products were electrophoresed on 0.8% agarose gels. PCR products were purified using ExoSAP-IT (Affymetrix, Santa Clara) and analyzed by standard Sanger di-deoxy nucleotide sequencing (DNA Sequencing Core Facility at Baylor College of Medicine, Houston).
Genome-wide Genotyping
To further investigate family relationships and the haplotype structure of variant alleles, we performed genome-wide SNP genotyping on Illumina HumanOmniExpress (families HOU1338 and HOU1333) and HumanOmni2.5 (families HOU1926 and HOU1380) microarrays (Illumina). Whole-genome amplification, fragmentation, hybridization, enzymatic single-base extension, slide staining, and washing were performed according to the manufacturer's instructions (Illumina). Microarrays were scanned on an Illumina iScan System. GenomeStudio software v2011.1 (Illumina) was used for SNP clustering, genotype calling, data intensity analysis, and the generation of the B allele frequency plots in Figure 3A . Copy number variation (CNV) partition was used for copy number and absence of heterozygosity analyses. For the last family (HOU1981; samples BAB4980 and BAB4981), B allele frequencies were determined from the whole exome data, i.e., by computing the variant/ total reads ratio for each SNP. The regions with absence of heterozygosity were identified using in-house scripts in R language (http://www.r-project. org) and Circular Binary Segmentation algorithm implemented in DNAcopy R package (Olshen et al., 2004) .
Identity-by-Descent Estimation PED and MAP files were exported from GenomeStudio and analyzed in PLINK. Because two different microarrays were used in the study, merged PED and MAP files were generated, which included only the 668,800 SNPs that were common to both arrays. Genotyping rate for this subset color coded to illustrate the cortical thickness from 0 mm (blue) to 1.5 mm (red, more thick 
Bioinformatics
The functional impact of the p.R140H substitution was assessed by considering conservation scores from PhyloP (Siepel et al., 2006) , GERP (Cooper et al., 1998) , and LRT (Chun and Fay, 2009 ) and, additionally, functional prediction scores from PolyPhen-2 (Adzhubei et al., 2010) , SNAP (Bromberg et al., 2008) , SIFT (Kumar et al., 2009) , and MutationTaster (Schwarz et al., 2010) , which are computational algorithms that estimate the detrimental effect of nonsynonymous substitutions based on statistical and machine learning models. Graphical representations of molecular models were prepared with PyMol (The PyMOL Molecular Graphics System, Schrö dinger).
OFC Calculations
WHO head circumference data are only available from birth to age 5 years. Therefore, we used head circumference data from the literature for boys and girls starting from birth to 18 years (Roche et al., 1987) . For time points that were not available in the primary data, we interpolated the values for both mean and SD using the R statistical programing language (R Core Development Team).
Histology and Immunohistochemistry
Clp1 K/K mutant mice were generated as described (Hanada et al., 2013) and maintained according to institutional guidelines. Whole brains were fixed in 4% paraformaldehyde, washed in PBS, dehydrated, and paraffin embedded according to standard protocols. For all procedures, 2-to 5-mm-thick coronal sections of formalin-fixed paraffin-embedded mouse brains were used. For hematoxylin and eosin staining (H&E), routine protocols were used. For immunohistochemical analysis, blocking of endogenous peroxidase activity was performed with 0.3% H 2 O 2 for 15 min on deparaffinated sections at room temperature, followed by treatment in a microwave oven (750 W) for 15 min in 10 mM citrate buffer (pH 6.0) for antigen retrieval before applying primary antibodies. Then, the first antibody in blocking buffer (5% goat serum/45% Tris buffered saline [pH 7.6] [TBS]/0.1% Triton X-100 in antibody diluent solution [Zytomed]) was applied overnight at 4 C. The following antibodies were used: rabbit polyclonal anti-Iba-1 (Iba-1, Wako Chemicals), mouse monoclonal anti-GFAP (Dako), mouse monoclonal antibody against neuronal nuclear antigen (NeuN, Chemicon), mouse monoclonal anti-Calbindin D-28K antibody (Sigma-Aldrich), mouse monoclonal anti-Neurofilament 200 antibody (Sigma-Aldrich), rabbit polyclonal anti-Pax6 (Covance), rabbit polyclonal antiTbr1 (Abcam), rabbit polyclonal anti-cleaved caspase 3 (Cell Signaling Technology), and anti-Ki67 (Novocastra). Histofine universal immunoperoxidase polymer and Histofine Mouse Stain Kit (Nichirei Biosciences) were applied after washing with TBS. The peroxidase reaction was detected using diaminobenzidine (Sigma-Aldrich) as chromogen. Counterstaining was performed using alum-hematoxylin. For immunofluorescence staining, Alexa Fluor 488 or 555 (Molecular Probes) was used as a secondary antibody with Hoechst 33342 for nuclear staining. Some quantifications were done using the public NIH Image J 1.46 software on comparable sections taken at the same, defined anterior-posterior level.
MRI
Clp1
K/K mutant mice and wild-type mice were analyzed using MRI. These data are published using an ultra-high-field 15.2 Tesla horizontal Biospec scanner (152/11, Bruker, Ettlingen). The magnet has a free bore of 110 mm and is equipped with actively shielded gradients (1,000 mT/m) and third-order shims. All scans were performed using a whole-body transmitter/receiver quadrature coil with an inner diameter of 35 mm. The SNR improvement of the high field allowed us to obtain from E16.5 and E18.5 mouse embryos 3D diffusion weighted spin echo sequences (TR/TE = 500/16.5 ms, 16 averages, b factor = 650 s/mm2) with FOV 12 3 12 3 8 mm with an imaging matrix 240 3 240 3 40 resulting in a spatial resolution of 50x50x200 mm. The same approach was taken to scan adult mouse brains, with the modification that the FOV (16 3 16 3 8 mm) and, consequently, the imaging matrix (320 3 320 x 40) had to be adjusted to keep the same resolution and total measurement time (NEX 9). For the adult brains, a b factor of 300 s/mm2 resulted in better contrast of the different brain structures. For images of whole embryos, we used a 7T whole-body scanner. These images were acquired with a standard turbo spin echo sequence (TE 48 ms, TR 380 ms) with a voxel resolution of 78 3 78 3 500 mm 3 (J. Friske et al., 2012, ESMRMB, conference) .
MRI Image Analysis
For each 3D image data set, the bulbus olfactorius, the cortex, the cerebellum and, for the adult brains, the hippocampus were manually segmented using the AMIRA software (V 5.5, VSG). Based on these segmentations, surface renderings of the individual segmented brain structures were displayed onto a representative horizontal MR slice at the ventral eye position using AMIRA visualization modules. The thickness of the cortex was determined at each vertex by computing the distance along the vertex normal to the normal's intersection with the closest triangle of the cortex. The resulting scalar field was surface mapped onto the surface rendering of the cortex. Geometric properties (volume, principal axes, and form factors) of each segmented brain structure were calculated using MagnAn (BioCom GbR).
Preparation of NPCs
Preparation of embryonic neuroepithelial cells containing neural precursor cells (NPCs) was performed as previously described (Shiraishi et al., 2010) . Cerebral cortices from embryonic day 14.5 pups were dissected in Hank's balanced salt solution and mechanically dissociated using a micropipette. After centrifugation, cells were plated in a 60 mm culture dish coated with poly-L-ornithine (Sigma) and recombinant human fibronectin (R&D). Cells were cultured in a neural progenitor maintenance medium (NPMM) bullet kit (Lonza). The medium was changed every other day. After 4 days of expansion of NPCs, cells were replated and cultured with 100 mM H 2 O 2 or with and without EGF and FGF for induction of cell death. 100 mM zVAD-fmk (BD bioscience) or 10 mM N-acetylcysteine (Sigma) were used as pan-caspase inhibitor or antioxidant, respectively. After 24 hr, cell survival was evaluated with immunostaining for cleaved caspase 3.
Statistics
Comparisons between groups were made by two-sided Student's t test. A p value less than 0.05 was considered significant.
ACCESSION NUMBERS
The GEO accession number for the tRNA sequencing data reported in this paper is GSE53391. 
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